火傷(Burns)：治療薬開発パイプライン動向（2015年上半期版）...市場調査レポートについてご紹介

Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Burns Overview 9
Therapeutics Development 10
Pipeline Products for Burns – Overview 10
Pipeline Products for Burns – Comparative Analysis 11
Burns – Therapeutics under Development by Companies 12
Burns – Therapeutics under Investigation by Universities/Institutes 14
Burns – Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Unknown Stage Products 18
Burns – Products under Development by Companies 19
Burns – Products under Investigation by Universities/Institutes 21
Burns – Companies Involved in Therapeutics Development 22
Adocia 22
AlgiPharma AS 23
Biogenomics Limited 24
Birken AG 25
CytoTools AG 26
Destiny Pharma Ltd. 27
Fibrocell Science, Inc. 28
HanAll Biopharma Co., Ltd. 29
Kasiak Research Pvt. Ltd. 30
Kuros Biosurgery AG 31
MediWound Ltd. 32
Novan, Inc. 33
Novartis AG 34
Se-cure Pharmaceuticals Ltd. 35
Stemnion, Inc 36
Stratatech Corporation 37
USV Limited 38
Vida Therapeutics Inc. 39
Xiber Science GmbH 40
Burns – Therapeutics Assessment 41
Assessment by Monotherapy Products 41
Assessment by Target 42
Assessment by Mechanism of Action 44
Assessment by Route of Administration 46
Assessment by Molecule Type 48
Drug Profiles 50
albumin (human) (recombinant) – Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Amnion Derived Cellular Cytokine Solution – Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
azficel-T – Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
bromelains – Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
BVS-857 – Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
coagulation factor XIVa (human) – Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Drug for Dermatology and Infectious Diseases – Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
epidermal growth factor biosimilar – Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
G-10 – Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
HL-156FIB – Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
IMSP-001 – Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
KUR-212 – Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
Monoclonal Antibody Conjugated for Burns and Wounds – Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
OleogelS-10 – Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
Oligomer G for Wounds And Burns – Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
PEP-04 – Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Protein to Activate FGFR for Dermatology, CNS, Cardiovascular and Musculoskeletal Disorders – Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
Recombinant Protein to Agonize Platelet Derived Growth Factor Receptor for Metabolic and Dermatology Diseases – Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
Refaheal – Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
SC-106 – Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
Small Molecule for Chronic Wounds and Burns – Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
StrataGraft Skin Tissue – Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
V-2248 – Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
XF-70 – Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
Xib-1302 – Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
Burns – Recent Pipeline Updates 80
Burns – Dormant Projects 85
Burns – Discontinued Products 87
Burns – Product Development Milestones 88
Featured News & Press Releases 88
Nov 03, 2014: MediWound Initiates Post-Marketing Study with NexoBrid to Treat Severe Burns in Pediatric Patients 88
Jul 16, 2014: MediWound Announces NexoBrid Marketing Approval From Israeli Ministry of Health 88
May 12, 2014: MediWound Completes Recruitment of Commercial Management Team in Europe 89
May 08, 2014: MediWound Expands Distribution of NexoBrid to Russia Through Agreement With Genfa Medica 91
Sep 23, 2012: Positive Recommendation for Marketing Authorization from the European Medicines Agency for its innovative drug – NexoBrid 92
Aug 12, 2009: Kuros Announces Encouraging Phase IIa Data With KUR-212 In Patients With Burns Requiring Mesh Grafting 93
Aug 11, 2008: Kuros Announces Results Of One-Month Follow-Up Of Phase IIa Trial Of KUR-212 In Patients With Burns Requiring Mesh Grafting 93
Feb 04, 2008: Kuros Completes Patient Recruitment In Phase Lia Trial Of KUR 212 In Patients With Severe Burns Requiring Meshed Skin Grafting 94
Appendix 95
Methodology 95
Coverage 95
Secondary Research 95
Primary Research 95
Expert Panel Validation 95
Contact Us 95
Disclaimer 96